Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance) | Zendy

Lawrence N. Shulman | Zendy; Donald A. Berry | Zendy; Constance Cirrincione | Zendy; Heather P. Becker | Zendy; Edith A. Perez | Zendy; Ruth O’Regan | Zendy; Silvana Martino | Zendy; Charles L. Shapiro | Zendy; Charles Schneider | Zendy; Gretchen Kimmick | Zendy; Harold J. Burstein | Zendy; Larry Norton | Zendy; Hyman B. Muss | Zendy; Clifford A. Hudis | Zendy; Eric P. Winer | Zendy

Open Access

Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)

Author(s) -

Lawrence N. Shulman,

Donald A. Berry,

Constance Cirrincione,

Heather P. Becker,

Edith A. Perez,

Ruth O’Regan,

Silvana Martino,

Charles L. Shapiro,

Charles Schneider,

Gretchen Kimmick,

Harold J. Burstein,

Larry Norton,

Hyman B. Muss,

Clifford A. Hudis,

Eric P. Winer

Publication year - 2014

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2013.53.7142

Subject(s) - medicine , breast cancer , cyclophosphamide , hazard ratio , toxicity , adjuvant , chemotherapy , oncology , paclitaxel , cancer , clinical endpoint , surgery , randomized controlled trial , confidence interval

Optimal adjuvant chemotherapy for early-stage breast cancer balances efficacy and toxicity. We sought to determine whether single-agent paclitaxel (T) was inferior to doxorubicin and cyclophosphamide (AC), when each was administered for four or six cycles of therapy, and whether it offered less toxicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research